Inhibitors of prostaglandin production, designated as classical non-steroidal antiinflammatory drugs (NSAIDs) and acting on the base of non-selective inhibition of cyclooxygenases, have been found in numerous studies to potentiate recovery of perturbed haematopoiesis by removing the negative feedback control mediated by prostaglandins. However, classical NSAIDs show pronounced undesirable gastrointestinal side effects, which limits the possibility of their utilization for various pathophysiological states including myelosuppression. Specific cyclooxygenase-2 (COX-2) inhibitors, targeted at selective inhibition of this inducible cyclooxygenase isoform and having much better gastrointestinal side effect profile, have been found in recent studies to retain the haematopoiesisstimulating effects of classical NSAIDs. These results suggest that the indication spectrum of selective COX-2 inhibitors may be extended to the indication of myelosuppression of various etiology. Combining the anti-tumour and haematopoiesis-stimulating activities in a single COX-2 inhibitor may have a positive clinical impact.
Introduction
This paper briefly summarises the hitherto accumulated data on stimulation of haematopoiesis by pharmacologically induced inhibition of prostaglandin production and outlines directions for further reserach in this area.
Haematopoietic tissue is a compartmentally organised system of cells which undergo the development from the level of stem cells through the developmental stages of progenitor cells and morphologically recognizable precursor cells to become functional mature blood cells of several lineages. These processes of differentiation and proliferation are under the influence of a number of cytokines, growth factors, and other regulatory molecules (see example, [1] ) and, as will be shown here, also prostaglandins. Cyclooxygenases, also known as prostaglandin H-2 synthases, are heme-containing enzymes which catalyse the first committed step in prostaglandin synthesis. Their function consists in catalysing two distinct reactions, namely cyclisation of arachidonic acid to form prostaglandin G 2 and hydroperoxidation of prostaglandin G 2 to form prostaglandin H 2 . This is subsequently converted to biologically active products including, among others, prostaglandin E 2 , which participates in the regulation of haematopoiesis (see, example, [2] [3] [4] ). Cyclooxygenase inhibition represents the mechanism of the effects of non-steroidal anti-inflammatory drugs (NSAIDs) (see, example, [5] ). NSAIDs are massively clinically employed for the treatment of inflammatory states (see, example, [6] ), but also in other indications like the prevention (see, example, [7] ) and treatment of cancer (see, example, [8] ). In particular, the area of treatment of cancer may be closely related to the topic of haematological effects of NSAIDs presented in this review, because myelosuppression belongs to frequent undesirable side effects of oncological therapy with cytotoxic drugs. Myelosuppression occurs also as a result of an exposure of the organism to sublethal or lethal doses of ionising radiation in situations like medical applications of ionising radiation, nuclear accidents or contingent terrorist attacks using radiological and nuclear devices. When discussing the latter subject, a panel of specialists listed the areas of developing new radioprotectors and new therapeutic agents for treating persons exposed to ionising radiation among those with top research priority [9] . These facts taken together strongly suggest that haematopoiesis-modulating effects of NSAIDs are worth of studying.
Hematopoiesis and non-selective cyclooxygenase inhibitors
Prostaglandins were shown in the eighties of the last century to inhibit the proliferation of haematopoietic progenitor cells and to reduce the cellularity of haematopoietic organs [10] . However, the administration of an inhibitor of prostaglandin synthesis and NSAID agent, indomethacin, to mice led to splenic erythropoiesis and an increase of granulocytemacrophage progenitor cells in the bone marrow [11] . These and other findings confirmed the hypothesis that prostaglandins, especially those of the E type, are negative feedback factors for both the regulation of granulopoiesis and the proliferation of more primitive haematopoietic cells [12] [13] [14] . Also, attention was paid to whether the regulatory actions of prostaglandins and inhibitors of their production were related directly to the target haematopoietic cells or whether other cells played a role in mediation of these regulatory processes. It was found that monocytes/macrophages were producers of prostaglandins as well as of regulatory cytokines and haematopoietic growth factors (see, example, [15] ) and that production of cytokines by macrophages could be modulated both by exoge-nous prostaglandins (see, example, [16] ) and by administration of NSAIDs (see, example, [17, 18] ). These findings strongly suggest that an indirect mechanism, i.e. mediation through cells not directly involved in haematopoietic lineages directed at production of erythrocytes, granulocytes, lymphocytes or platelets, plays a key role in the modulation of haematopoiesis via the regulatory feedback system mediated by prostaglandins.
Various NSAIDs were subsequently reported to stimulate the proliferation of haematopoietic stem cells [19] , to enhance bone marrow and splenic haematopoiesis [20, 21] , and even to up-regulate bone marrow erythropoiesis [22] . The results on the effects of NSAIDs on haematopoiesis were utilised by a number of research groups for the experimental treatment of postirradiation haematopoietic failure by substances from this group of drugs. Favourable effects, manifested by the enhancement of postirradiation haematopoietic recovery, were observed in the laboratory of the authors, as well as in other laboratories not only after pre-irradiation application of NSAIDs (indomethacin, diclofenac, or flurbiprofen) [23] [24] [25] , but also when NSAIDs were given in conditions of fractionated irradiation [26] [27] [28] or after irradiation [29] [30] [31] . Additionally, these effects were observed when the administration of NSAIDs followed lethal irradiation and syngeneic bone marrow transplantation [32] . Some stimulation of haematopoietic recovery was also found when giving indomethacin repeatedy to continuously irradiated rats [33] . Administration of diclofenac led to the stimulation of haematopoiesis in tumor-bearing mice as well [34] . Moreover, diclofenac was observed to potentiate haematopoiesisstimulating effects of an immunomodulator glucan when the two drugs were administered concommitantly either before a single dose of gamma-rays [35] or before each radiation dose in repeatedly irradiated mice [36] . Mutually potentiating haematological effects were also found when diclofenac or indomethacin were given in a protective pre-irradiation regimen concurrently with immunomodulators muramyl tripeptide phosphatidylethanolamine [37, 38] or broncho-vaxom [39] . Concommitant administration of indomethacin or diclofenac with the chemical radioprotectors cystamine or WR-2721 (S-2-(3-aminopropylamino)ethylphosphorothioic acid) was observed to enhance the haematopoiesis-stimulating efficiency of the chemical radiprotectors [40] [41] [42] . A positive role of NSAIDs in stimulation of recovery of haematopoiesis damaged by cytotoxic antitumour drugs was also reported [43] [44] [45] . The above studies revealed that NSAIDs enhanced a wide range of haematological parameters in experimental animals, including those illustrating the state of the compartments of multipotent and committed progenitor cells, total cellularity of haematopoietic organs, and numbers of mature peripheral blood cells. In 1994 the positive results with NSAIDs on stimulation of haematopoiesis obtained in animal experiments directed A.S. Michalowski to state that "Further studies on anti-inflammatory drug treatment of radiation damage to normal organs are justified and desirable" [46] . Nevertheless, administration of classical NSAIDs, including those tested in the above-mentioned studies, is frequently accompanied by undesirable side effects. Of these side effects, the most clinically relevant ones are those that damage the gastrointestinal tract. These are observed not only in man (see, example, [47] ) but also in experimental animals [48] . These effects are directly linked to the ability of NSAIDs to inhibit the synthesis of prostaglandins, because prostaglandins have cytoprotective activity in the gastrointestinal mucosa [49] . In connection with the above-listed results on positive effects of NSAIDs on haematopoiesis in experimental animals exposed to ionising radiation, it is necessary to stress that these results were obtained after irradiating the animals with sublethal radiation doses. This induced pure bone marrow syndrome of the acute radiation disease without serious damage to the gastrointestinal system. However, after exposure to lethal radiation doses, which damage both the bone marrow and the gastrointestinal mucosa, a reduced survival and appearance of early deaths were observed in mice treated with NSAIDs either before [50] or after irradiation [51] . Histological evaluation revealed pathological changes in the NSAIDs-treated animals, including partial loss of the intestinal epithelium [51] .
A number of derivatives of common classical NSAIDs were synthesised and tested with the aim to obtain drugs with reduced gastrointestinal side effects, and among them was a nitroderivative of the commonly clinically used NSAID flurbiprofen, flurbiprofen 4-nitroxybutylester [52] . Flurbiprofen 4-nitroxybutylester was tested in the laboratory of the authors to assess its radioprotective effects; stimulatory action on haematopoiesis after sublethal irradiation and insignificanly enhanced survival after lethal irradiation were observed [53] .
Haematopoiesis and selective COX-2 inhibitors
Cyclooxygenases carrying out prostaglandin synthesis exist in two isoforms, namely cyclooxygenase-1 (COX-1), which is expressed constitutively in a variety of tissues including the gastrointestinal tract, and cyclooxygenase-2 (COX-2), which is inducible and is responsible for the production of prostaglandins during inflammatory states [54] . The turning point in the research aimed at reducing the undesirable gastrointestinal effects of NSAIDs appeared with the synthesis and subsequent practical utilisation of selective COX-2 inhibitors [55] . Although experimental data exist which describe a positive role for COX-2 in healing gastric lesions [56, 57] , clinical data clearly show a reduced risk of gastrointestinal complications after administration of selective COX-2 inhibitors when compared with the classical NSAIDs [58] . The utilisation of selective COX-2 inhibitors instead of classical NSAIDs for the stimulation of haematopoiesis could be advantageous for obvious reasons, especially for potential clinical indications in patients. These are, in particular, myelosuppression resulting from exposure to ionizing radiation or from treatment with cytotoxic anti-tumour drugs. For both these clinical states, a low incidence and intensity of gastrointestinal side effects would be desirable.
The first report giving incomplete haematological evaluation about the effects of pharmacologically induced COX-2 inhibition appeared in 1998: Shoup et al. [59] reported a significant augmentation of total white blood cells and neutrophils in experimentally burned rats treated with the selective COX-2 inhibitor NS-398.
In 1999, Lorenz et al. [60] published their results of analysis of haematopoiesis in non-treated and 5-fluorouracil-treated COX-2-deficient mice. They concluded that COX-2 was essential for haematopoietic regeneration in COX-2-deficient mice damaged by 5-fluorouracil [60] . However, an alternative interpretation of their findings, stemming from the hypothesis about the downregulatory role of COX-2 in haematopoiesis, is possible. In non-treated mice, Lorenz et al. reported a significant increase in the numbers of both neutrophils and lymphocytes in COX-2-deficient mice in comparison with wild-type mice [60] . This result gives evidence for accelerated haematopoiesis and, thus, higher cell cycling activity under conditions of missing COX-2. The impaired regeneration of haematopoiesis in 5-fluorouracil-treated COX-2-deficient mice observed by these authors [60] then may be due to higher cell damage induced by the cell cycle-specific drug 5-fluorouracil.
Promising results of experiments testing haematological effects of another of the selective COX-2 inhibitors, meloxicam [61] , in irradiated mice have been recently published by the authors of this review: meloxicam has been shown to stimulate both granulopoiesis and erythropoiesis when administered either singly before irradiation of mice with a dose of 6.5 Gy gamma-rays or repeatedly (four times) after irradiation with the dose of 4 Gy [62] . It follows from these results that selective inhibition of COX-2 is sufficient for significant stimulation of haematopoiesis.
Directions of further research
Experiments testing haematopoiesis-modulating effects of selective COX-2 inhibitors on animals exposed to ionising radiation should be supplemented with studies of their effects at higher doses. Besides myelosuppression, such dose may also evoke gastrointestinal radiation syndrome. Thus, it is possible that the gastrointestinal tolerance induced by selective COX-2 inhibitors may be reflected by the better survival of lethally irradiated and COX-inhibitor-treated animals in comparison with non-treated and classical NSAIDstreated ones.
Studies on the haematological effects of selective COX-2 inhibitors on experimental animals in which myelosuppression would be induced by treatment with cytotoxic antitumour drugs should be performed. Selective COX-2 inhibitors have shown anti-tumour properties in a number of studies. For example, meloxicam, whose haematopoiesisstimulating effects have been already demonstrated [62] , has been repeatedly reported to show anti-tumour activities [63] [64] [65] . A combination of anti-tumour and haematopoiesisstimulating effects in one drug would be very advantageous.
The effects of combined administration of selective COX-2 inhibitors with haematopoietic growth factors, (e.g. granulocyte colony-stimulating factor G-CSF), should be studied. G-CSF is a rather costly drug (see example [66] ). If a part of the total dose of G-CSF administered to a patient could be substituted by a cheaper drug, like a COX-2 inhibitor, the total cost of the therapy would be cut back.
Finally, clinical studies on haematological effects of COX-2 inhibitors should be commenced. Contingent positive outcome of these studies would significantly extend the indication spectrum for these interesting drugs.
